Prevention and management of diarrhea associated with naldemedine among patients receiving opioids: a retrospective cohort study.

ABSTRACT:

Background

Naldemedine, a novel peripherally-acting mu-opioid receptor antagonist, has improved opioid-induced constipation in randomized controlled trials. The most frequent adverse event of naldemedine is diarrhea, which can cause abdominal pain and often leads to treatment discontinuation. We aimed to identify risk factors and appropriate management strategies for key adverse events including diarrhea associated with naldemedine, since those have not been extensively studied.

Methods

We conducted a multi-center retrospective cohort study. Eligible patients had cancer, had undergone palliative care at participating centers, had been prescribed regular opioids, and had taken at least one dose of naldemedine between June 2017 and March 2018. The primary endpoint was the inci

SUBMITTER: Takagi Y 

PROVIDER: S-EPMC6995158 | biostudies-literature | 2020 Jan

REPOSITORIES: biostudies-literature